Close Menu

NEW YORK – Adaptive Biotechnologies reported after the close of the market on Wednesday that its fourth quarter revenues increased 41 percent year over year.

For the three months ended Dec. 31, 2019, the Seattle-based immune sequencing firm tallied revenues of $24.2 million compared to $17.2 million a year ago, and well above analysts' average estimate of $21.7 million.

Fourth quarter sequencing revenue increased 33 percent to $13.9 million from $10.5 million, while development revenue grew 53 percent to $24.2 million from $17.2 million a year ago.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.